Effect of Recombinant Human Adenovirus Type 5 Injection Combined with Haploidentical Natural Killer Cell Immunotherapy on Immune Function and Adverse Reactions in Patients with Malignant Ascites Caused by Ovarian Cancer

Abstract

Objective: To explore the effect of recombinant human adenovirus type 5 injection combined with haploidentical natural killer cell immunotherapy on immune function and adverse reactions in patients with malignant ascites caused by ovarian cancer (OC). Methods: From January 2018 to September 2019, 65 patients with advanced OC combined with malignant ascites who received treatment in the oncology department of our hospital were collected. According to the treatment methods, the patients were assigned to study group (SG) (35 cases) and control group (CG) (30 cases). In CG, patients were treated with NK cell reinfusion. SG: On the basis of the CG, the recombinant human adenovirus type 5 injection was injected directly into tumour. The peripheral blood mononuclear cells of lineal relatives of all patients were cultivated by antibody coating and co-stimulation with various cytokines, and the NK cells cultured in vitro were returned to the patients for infusion twice on the 14th and 15th days, respectively. The clinical efficacy, changes of serum tumour markers, changes of immune function indicators and adverse effects were compared between the two groups. Results: The objective remission rate of clinical efficacy in the SG was obviously higher than that in the CG. Before therapy, the levels of serum carcinoembryonic antigen, carbohydrate antigen 242, carbohydrate antigen 19-9, alpha-fetoprotein and neuron specific enolase had no statistically significant difference in both groups (P>0.05). After therapy, the level of each index in the SG was better than that in the CG, with statistically significant difference (P<0.05). After therapy, the levels of peripheral NK cells, CD4+/CD8+ ratio, CD3+CD4+ and CD3+ level in SG were obviously higher than those before treatment, while the levels of CD4+CD25+ were obviously lower than those before treatment, and the indexes in the SG were obviously better than those in the CG (P<0.05). Before therapy, there was no obvious difference in quality of life between the two groups. After treatment, the overall quality of life in the SG was higher than that in the CG, with statistically significant difference (P<0.05). The incidence of hepatic and renal insufficiency had no statistically significant difference between SG and CG (P>0.05). However, the incidence of nausea, vomiting, abdominal pain and diarrhea in the SG was obviously lower than that in the CG, with statistically significant difference (P<0.05). Conclusion: Recombinant human adenovirus type 5 injection combined with haploidentical natural killer cell immunotherapy can better recover the immune function and reduce the incidence of adverse reactions in patients with malignant ascites caused by OC.